ICR welcomes recommendation of talazoparib for advanced breast cancer 19 Jan 2024 The Institute of Cancer Research, London, strongly welcomes the news that talazoparib (trade name Talzenna) has been recommended by NICE for the treatment of advanced breast cancer. Find out more Show/Hide
‘Search and destroy’ treatment improves quality of life for patients with advanced prostate cancer 08 Sep 2023 A new radioactive medicine that seeks out tumour cells to deliver a targeted dose of radiation greatly improves quality of life for patients with advanced prostate cancer, a phase III study finds. Find out more Show/Hide
ICR hails ‘momentous’ recommendation of olaparib for breast and prostate cancer 05 Apr 2023 The Institute of Cancer Research, London, has hailed the ‘life-changing’ decision by NICE to recommend that the targeted drug olaparib can be used for NHS patients with both early-stage breast cancer and prostate cancer. Find out more Show/Hide
The ICR responds to NICE’s recommendation not to approve abiraterone as first-line treatment for advanced prostate cancer 15 Jul 2021
ASCO 2021: Trial shows benefits of targeted drug against early-stage breast cancer with inherited BRCA mutation 03 Jun 2021
ICR welcomes NICE’s decision to reassess abiraterone as first-line treatment for advanced prostate cancer 29 Oct 2020
Men in England and Wales miss out on abiraterone as first-line treatment for advanced prostate cancer 26 Jun 2020